There are reports that many immunoinhibitory receptors are affected when infected with the new coronavirus (SARS-CoV-2).
https://pubmed.ncbi.nlm.nih.gov/33200082/
Compared to SARS-CoV-1, Influenza A virus, and Respiratory synergy virus, SARS-CoV-2 has significantly increased the expression of the following immunoinhibotory receptors:
CEACAM1
SIGLECS
LILRB3
LILRB4
LILRB5
CLEAN12A
It concluded that these inhibitors could also be effective candidates for treatment of COVID-19.
